At a Glance
- Company: Intellia Therapeutics (Nasdaq: NTLA)
- Location: Cambridge, Massachusetts
- Headline figures: Full clinical holds lifted on two programs
- Focus area: In vivo CRISPR therapies for ATTR and HAE
- Next steps: Dose escalation; expanded cohort enrollment
What happened?
The FDA lifted full clinical holds on Intellia Therapeutics’ NTLA-2001 and NTLA-2002 programs on 4 March 2026, clearing both CRISPR/Cas9 therapies to resume patient dosing. NTLA-2001 targets transthyretin (ATTR) amyloidosis; NTLA-2002 addresses hereditary angioedema (HAE). Holds stemmed from patient safety events; resolution followed enhanced risk mitigation.
Why does it matter?
In vivo CRISPR enables one-time liver editing without ex vivo manipulation; NTLA-2001 showed 89% TTR reduction at 1.1mg with 24-month durability. Hold lifts de-risk pivotal trials in $10B+ ATTR market and rare disease HAE space, validating safety profile after initial pauses.
Who’s behind it?
Intellia Therapeutics pioneers systemic CRISPR editing; Regeneron co-develops NTLA-2001. CEO John Leonard highlighted FDA collaboration resolving hepatic safety concerns via monitoring protocols.
How was it achieved?
Holds imposed 2025 after elevated liver enzymes and adverse events; Intellia implemented dose controls, eligibility screening and serial biomarker monitoring. FDA review confirmed mitigable risks, allowing cohort expansions.
What’s next?
NTLA-2001 phase 3 MAGNITUDE trial enrollment accelerates; NTLA-2002 phase 1/2 HAE Cohort 1 dosing resumes Q2 2026. Full phase 1/2 data expected mid-year supporting pivotal designs.
What are people saying?
CEO Leonard: “Significant milestone… resume clinical progress.” Analysts: “De-risks lead assets; multi-billion peak sales potential.”